Exhibit 3.1
Registrar of Companies
Government Administration Building
133 Elgin Avenue
George Town
Grand Cayman
YishengBio Co., Ltd (ROC# 368187) (the “Company”)
TAKE NOTICE that at an Extraordinary General Meeting of the Shareholders of the Company held on 23 September 2022, the following special resolutions were passed and became effective on 16 March 2023:
BUSINESS COMBINATION TRANSACTIONS AND TRANSACTION DOCUMENTS
RESOLVED AS SPECIAL RESOLUTIONS, that, it is in the best interests of the Company to negotiate, execute and consummate the Business Combination Transactions and any related transactions, including but not limited to, the Company Capital Restructuring (as defined below), the First Merger, the Second Merger, the Listing and related issuance of Post-Consolidation Ordinary Shares and Post-Consolidation Company Warrants,
RESOLVED AS SPECIAL RESOLUTIONS that, it is in the best interests of the Company to negotiate, execute and deliver each of the Transaction Documents,
RESOLVED AS SPECIAL RESOLUTIONS that, it is in the best interests of the Company to negotiate, execute and adopt each of the Amended Company Charter (as defined below), effective immediately prior to the First Merger Effective Time and the Amended Company Share Incentive Plan, conditional and effective only upon the consummation of First Merger in accordance with the Business Combination Agreement.
COMPANY CAPITAL RESTRUCTURING
RESOLVED AS SPECIAL RESOLUTIONS that, it is in the best interests of the Company to consummate the Company Capital Restructuring (as defined below) contemplated by the Transaction Documents, in accordance with and subject to applicable law and the Transaction Documents, and the Company Capital Restructuring (as defined below) hereby is, in all respects, authorized and approved, conditional and effective only upon the consummation of First Merger in accordance with the Business Combination Agreement; and
FURTHER RESOLVED AS SPECIAL RESOLUTIONS that each of the following steps (together, the “Company Capital Restructuring”) be and are hereby approved and authorized, conditional and effective only upon the consummation of First Merger in accordance with the Business Combination Agreement:
(i) | Each Series A Preferred Share of the Company with a par value of US$0.000005 per share (the “Series A Preferred Shares”) and each Series B Preferred Share of the Company with a par value of US$0.000005 per share (the “Series B Preferred Shares”) that is issued and outstanding immediately prior to the First Merger Effective Time shall be converted (by way of re-designation) into one Ordinary Share of the Company with a par value of US$0.000005 per share, on a one-for-one, basis by virtue of and in accordance with the written consents of the |